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Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD. The impact of aripiprazole on the
response to HIV is unknown. The patient we report on was diagnosedHIV-positive in 1997 and has been treated with antiretroviral
therapy since then. In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder. On that occasion, blood
tests showed a significantly reduced CD4 count and a positive viral load. We treated this patient with aripiprazole and citalopram.
Mood, somatic symptoms, and occupational functioning progressively improved. The last blood examination showed an increase
in the CD4 count and a negative viral load. On the basis of the present case study and the review of the literature concerning the
effects of psychotropic agents on viral replication, we suggest that the use of aripiprazole in HIV-infected subjects warrants further
research.
1. Introduction
In November 2007 the Food and Drug Administration
(FDA) approved the use of aripiprazole as an adjunctive,
or add-on, treatment to antidepressant therapy in adults
with major depressive disorder (MDD). Aripiprazole is the
first medication approved by the FDA as an add-on treat-
ment for MDD [1], modulating the dopaminergic system.
Unlike typical and atypical antipsychotic drugs which act
as antagonists to the dopamine D2 receptor, aripiprazole
has a novel mechanism of action, causing it to act as a
partial agonist to the dopamine D2 receptor. Partial agonists
have a lower intrinsic activity to receptors than full agonists,
which allows them to act either as a functional agonist or a
functional antagonist, depending on the surrounding levels
of the naturally occurring neurotransmitter (full agonist). In
the absence of a full agonist, partial agonists show functional
agonist activity, binding to the receptor so as to produce a
response. In the presence of a full agonist, partial agonists
show functional antagonist activity, inasmuch as receptor
binding reduces the response from the level of that seen with
the full agonist [2].
Drugs active on the dopaminergic system, such as
methamphetamine, have been claimed to exert an effect on
HIV infectivity [3, 4]. Lento-viral replication seems to be
enhanced in peripheral blood mononuclear cells partially
through dopaminergic activity. Dopamine acts through
dopamine receptors (DRs), and classically DRs have been
studied on neurons. In addition, DR expression has been
reported in several types of peripheral blood leukocytes,
including T lymphocytes and monocytes. Dopamine recep-
tors have been shown to modulate the immune function
of T lymphocytes [5–7]. The data show clearly that, with
an increasing dose of methamphetamine, the replication of
Feline immunodeficiency virus (FIV) is induced [3, 4, 8].
Psychostimulants, such as cocaine and methamphetamine,
exert addictive and reinforcing effects through the eleva-
tion of extracellular dopamine (DA) levels in the CNS.
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The impact of aripiprazole, a dopamine stabilizer, on the
response to HIV in HIV-infected patients is unknown.
We present a case of resistant depression, somatoform
disorder, and panic disorder in an HIV-infected subject,
treated with aripiprazole as augmentation therapy. In this
case aripiprazole led, not only to significant improvement in
depressive symptomatology, but also to an improvement in
CD4 cell count and viral load.
2. Case Study
The case we wish to present involves a 37-year-old Caucasian
man, by trade a musician. Since adolescence, he has been
beset by mood instability (cyclotimia), irritability, severe
onicophagy, and obsessive-compulsive and impulsive per-
sonality traits, and hypochondria. He was in good health
until 1992 when he was confirmed as having a gastric ulcer
and put on omeprazole and prokinetics for several years. He
was diagnosed HIV-positive in 1997 and has been treated
with antiretroviral drugs since then (nevirapine and the
association of lamivudine and zidovudine). In spring 2008
he began to manifest acute episodes characterized by shivers,
nausea, retching, diarrhea, tremor, and paresthesias. He also
complained of cephalea, cervical and lumbar pain, middle
and late insomnia, decrease in appetite, fatigue, impairment
in occupational functioning, diminished ability to concen-
trate and recurrent concerns about his health. Because of this
symptomatology, he sought the advice of specialists in dif-
ferent fields (infective diseases, gastroenterology, neurology,
orthopedics), who prescribed several diagnostic tests (blood
tests, coproculture, X-ray of digestive tract, abdominal CT,
and cervical rachis MRN). Blood tests showed a CD4
count of 200 cells/μL and a viral load of 3000 copies/mL.
All the other diagnostic tests were negative. In the mean-
time, he was prescribed different therapies to control
anxiety, somatisation, and mood instability: prokinetics
(domperidone 30mg/die), omeprazole (20mg/die), levo-
sulpiride (50mg/die), lorazepam (3mg/die), trimipramine
(100mg/die) for 8 weeks, paroxetine (20mg/die) for 10
weeks, and mirtazapine (30mg/die) for 12 weeks. None
of these drugs led to substantial clinical improvement. In
September 2008 he came to our outpatient clinic owing to
persistent symptomatology. We diagnosed resistant major
depression, somatoform disorder (hypochondria), and panic
disorder. Resistant depression was defined as a depressive
episode with at least two previous failed antidepressant trials,
each lasting at least 6 weeks (stage II of antidepressant
resistance according to Thase and Rush) [9]. In concert with
a specialist in infective diseases, we decided to treat his psy-
chiatric symptomatology in order to improve his compliance
with antiretroviral therapy. In our experience low doses of
aripiprazole (up to 15mg/die) are effective as augmentation
therapy in depressed patients who are nonresponders to SSRI
or tricyclic antidepressants in monotherapy; so we chose
to use this drug for this patient, added on to citalopram
40mg/die. For states of anxiety, we avoided benzodiazepines
because of the patient’s tendency to abuse it. So we used
clonazepam 0.5mg/die only at the beginning of therapy.
Gradually, the frequency of the acute episodes decreased
and the intensity of symptomatology during these episodes
diminished. Mood, somatic symptoms, and occupational
functioning progressively improved. The last blood exami-
nation showed up an increase in CD4 count (400 cells/μL)
and a negative viral load.
3. Discussion
Mental disorders are highly prevalent in HIV-infected indi-
viduals, with about 48% of these patients having a psychiatric
disorder [10]. In HIV-infected patients, mental disorders
such as depression have been associated with increased risk
of poor medication adherence and HIV disease progression
[11]. Moreover, patients who are depressed or suffer from
anxiety or have substance abuse disorder at the time
of initiating antiretroviral therapy have poorer virological
responses to treatment. Improvement in depression after
treatment has been shown to improve quality of life and
increase in treatment adherence.
The availability of highly active antiretroviral therapies
(HAARTs) has not eliminated HIV-1 infection of the central
nervous system (CNS) or the occurrence of HIV-associated
neurological problems, which are both increasing due to
the longer lifespan of infected individuals on antiretroviral
therapies [12] and the poor ability of most antiretroviral
drugs to penetrate the blood-brain barrier [13, 14]. Human
immunodeficiency virus (HIV) enters the central nervous
system (CNS) soon after initial infection [15] resulting in
ongoing inflammation, as well as neurological damage that
leads to the development of HIV-associated neurocognitive
disorders (HANDs) in asmany as 50% of infected individuals
[16, 17]. HIV is thought to enter the brain through the
transmigration of infected monocytes across the blood-
brain barrier. Within the CNS, macrophages are the primary
source of HIV and the virus spreads primarily through the
infection of brain macrophages and microglia [18]. Infected
macrophages produce numerous factors that are neurotoxic
and contribute to the neurological damage that occurs in
HIV-infected individuals [19].
The effects of aripiprazole, a dopamine stabilizer, on
depressive symptoms are well documented [20], but its
effects on viral replication and immunologic system call for
further study.
In 2000 Kristiansen and Hansen found that some
psychotropic agents (flupentixol, paroxetine, femoxetine)
and their structural isomers inhibit HIV replication in
HIV-infected patients with AIDS related dementia [21],
suggesting the use of these psychotropic drugs in combi-
nation with antiretroviral therapy to control the condition.
Earlier investigations have shown that microorganisms with
high affinity to the nervous system are very sensitive to
neurotropic drugs [22–24]. Aripiprazole acts as a partial
agonist at dopamine D2, D3, and at serotonin 5-HT1A
receptors and as an antagonist at 5-HT2A receptors, so it
should be interesting to test its antiviral activity.
As regards aripiprazole’s immunological impact, we
know that several antidepressants (tricyclic, IMAO, SSRI,
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and bupropion) show up such an effect in that they exert
an immunomodulatory effect, reducing proinflammatory
cytokines and increasing anti-inflammatory cytokines [25].
Antidepressants seem to exert their immunological effect
both at central (CNS) and peripheral level (on activated
macrophages). Aripiprazole might also be effective in HIV-
infected patients for a specific immunological effect. Neu-
ropsychiatric disorders, in HIV-infected patients, seem to
occur, in part, through glial activation and release of cyto-
toxic chemokines and cytokines such as interferon-γ(IFN-γ)
[26]. In vitro, aripiprazole has a significant inhibitory
effect on IFN-γ-induced microglial activation, reducing the
generation of NO and TNF-α and suppressing the elevation
of [Ca2+] in microglia [27]. We suppose that aripiprazole has
the same effect in vivo on astrocytes activated by infection.
Another possible reason for the improvement in the
patient’s immune status is an indirect effect of aripipra-
zole on cortisol levels brought about by improvement in
depression. The dysregulation of the HPA axis function (e.g.,
increase in adrenocorticotrophin-releasing hormone and
cortisol levels) has been associated with stress and depression
in humans, and such dysregulation may negatively impact
the immune response. There are data supporting the fact
that glucocorticoids may affect HIV pathogenesis directly,
through increased viral replication, or more indirectly by
inhibiting the immune response to other pathogens. In fact,
in 1997 Christeff et al. [28] demonstrated that high levels
of plasma cortisol are negatively associated with CD4 cell
counts. Thus, aripiprazole’s effect on HIV replication and
CD4 counts may be partially explained by an indirect effect
on immune response brought on by decreased cortisol levels,
in turn induced by improvement in depressive symptoms.
As a final point, we cannot exclude the possibility that the
improvement in depression symptomology may result in an
increased adherence to antiretroviral treatment.
On the basis of the present case study and the review of
the literature about the effects of psychotropic agents on viral
replication, we suggest that the use of aripiprazole in HIV-
infected subjects warrants further research.
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